Evidence map›Paper›PMID 28127577›Full record

ArticleNPJ schizophrenia2017

Parkinsonian motor impairment predicts personality domains related to genetic risk and treatment outcomes in schizophrenia.

Juan L Molina, María Calvó, Eduardo Padilla, Mara Balda, Gabriela González Alemán, Néstor V Florenzano, Gonzalo Guerrero, Danielle Kamis, Beatriz Molina Rangeon, Mercedes Bourdieu and 6 more

Open access · goldAbstract read
In one paragraph

Article in NPJ schizophrenia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Juan L MolinaDepartment of Psychiatry and Behavioral Neurosciences, Morsani College of Medicine, University of South Florida , Tampa, FL, USA.
María CalvóFundación de Lucha contra los Trastornos Neurológicos y Psiquiátricos en Minorías, FULTRA, Buenos Aires, Argentina; Hospital Neuropsiquiátrico Dr Néstor Sequeiros, San Salvador de Jujuy, Argentina.
Eduardo PadillaFundación de Lucha contra los Trastornos Neurológicos y Psiquiátricos en Minorías, FULTRA, Buenos Aires, Argentina; Hospital Neuropsiquiátrico Dr Néstor Sequeiros, San Salvador de Jujuy, Argentina.
Mara BaldaDepartment of Psychiatry and Behavioral Neurosciences, Morsani College of Medicine, University of South Florida , Tampa, FL, USA.
Gabriela González AlemánFundación de Lucha contra los Trastornos Neurológicos y Psiquiátricos en Minorías, FULTRA , Buenos Aires, Argentina.
Néstor V FlorenzanoUnidad de Neurociencias, Dr J.J. Naón, Facultad de Medicina, Universidad de Buenos Aires , Buenos Aires, Argentina.
Gonzalo GuerreroFundación de Lucha contra los Trastornos Neurológicos y Psiquiátricos en Minorías, FULTRA, Buenos Aires, Argentina; Hospital Neuropsiquiátrico Dr Néstor Sequeiros, San Salvador de Jujuy, Argentina.
Danielle KamisDepartment of Psychiatry and Behavioral Neurosciences, Morsani College of Medicine, University of South Florida , Tampa, FL, USA.
Beatriz Molina RangeonFundación de Lucha contra los Trastornos Neurológicos y Psiquiátricos en Minorías, FULTRA, Buenos Aires, Argentina; Hospital Neuropsiquiátrico Dr Néstor Sequeiros, San Salvador de Jujuy, Argentina.
Mercedes BourdieuFundación de Lucha contra los Trastornos Neurológicos y Psiquiátricos en Minorías, FULTRA, Buenos Aires, Argentina; Hospital Neuropsiquiátrico Dr Néstor Sequeiros, San Salvador de Jujuy, Argentina.
Sergio A StrejilevichFundación de Lucha contra los Trastornos Neurológicos y Psiquiátricos en Minorías, FULTRA , Buenos Aires, Argentina.
Horacio A ConesaFundación de Lucha contra los Trastornos Neurológicos y Psiquiátricos en Minorías, FULTRA, Buenos Aires, Argentina; Unidad de Neurociencias, Dr J.J. Naón, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Javier I EscobarRutgers University-Robert Wood Johnson Medical School , New Brunswick, NJ, USA.
Igor ZwirDepartments of Psychiatry and Genetics, Washington University School of Medicine , St Louis, MO, USA.
C Robert CloningerDepartments of Psychiatry and Genetics, Washington University School of Medicine , St Louis, MO, USA.
Gabriel A de ErausquinDepartment of Psychiatry and Behavioral Neurosciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA; Division of Neurosciences and Department of Psychiatry and Neurology, UTRGV School of Medicine, Harlingen, TX, USA.
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia · ARUniversity of South Florida · USWashington University in St. Louis · USRutgers, The State University of New Jersey · USThe University of Texas Rio Grande Valley · USUniversity of Buenos Aires · AR

Funding

Genetics of Parkinsonism in a Special Population of Untreated SchizophreniaK08MH077220 · NIMH · WASHINGTON UNIVERSITY · PI DE ERAUSQUIN, GABRIEL ALEJANDRO · 2007 to 2013
$804k
INVESTIGATION ON THE MOVEMENT ABNORMALITIES & GENETICS OF SCHIZOPHRENIA (IMAGES)R21TW007882 · FIC · WASHINGTON UNIVERSITY · PI DE ERAUSQUIN, GABRIEL ALEJANDRO · 2008 to 2009
$271k
FIC NIH HHS R21 TW007882NIMH NIH HHS K08 MH077220
6 · The paper itself

Abstract

Identifying endophenotypes of schizophrenia is of critical importance and has profound implications on clinical practice. Here we propose an innovative approach to clarify the mechanims through which temperament and character deviance relates to risk for schizophrenia and predict long-term treatment outcomes. We recruited 61 antipsychotic naïve subjects with chronic schizophrenia, 99 unaffected relatives, and 68 healthy controls from rural communities in the Central Andes. Diagnosis was ascertained with the Schedules of Clinical Assessment in Neuropsychiatry; parkinsonian motor impairment was measured with the Unified Parkinson's Disease Rating Scale; mesencephalic parenchyma was evaluated with transcranial ultrasound; and personality traits were assessed using the Temperament and Character Inventory. Ten-year outcome data was available for ~40% of the index cases. Patients with schizophrenia had higher harm avoidance and self-transcendence (ST), and lower reward dependence (RD), cooperativeness (CO), and self-directedness (SD). Unaffected relatives had higher ST and lower CO and SD. Parkinsonism reliably predicted RD, CO, and SD after correcting for age and sex. The average duration of untreated psychosis (DUP) was over 5 years. Further, SD was anticorrelated with DUP and antipsychotic dosing at follow-up. Baseline DUP was related to antipsychotic dose-years. Further, 'explosive/borderline', 'methodical/obsessive', and 'disorganized/schizotypal' personality profiles were associated with increased risk of schizophrenia. Parkinsonism predicts core personality features and treatment outcomes in schizophrenia. Our study suggests that RD, CO, and SD are endophenotypes of the disease that may, in part, be mediated by dopaminergic function. Further, SD is an important determinant of treatment course and outcome.

Identifiers

PMID28127577
PMCPMC5226082
OpenAlexW2567895289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.